LLY

1,066.64

+0.73%↑

JNJ

204.97

+0.51%↑

ABBV

233.76

-1.02%↓

UNH

321.53

+0.68%↑

AZN

91.31

+0.33%↑

LLY

1,066.64

+0.73%↑

JNJ

204.97

+0.51%↑

ABBV

233.76

-1.02%↓

UNH

321.53

+0.68%↑

AZN

91.31

+0.33%↑

LLY

1,066.64

+0.73%↑

JNJ

204.97

+0.51%↑

ABBV

233.76

-1.02%↓

UNH

321.53

+0.68%↑

AZN

91.31

+0.33%↑

LLY

1,066.64

+0.73%↑

JNJ

204.97

+0.51%↑

ABBV

233.76

-1.02%↓

UNH

321.53

+0.68%↑

AZN

91.31

+0.33%↑

LLY

1,066.64

+0.73%↑

JNJ

204.97

+0.51%↑

ABBV

233.76

-1.02%↓

UNH

321.53

+0.68%↑

AZN

91.31

+0.33%↑

Начало・Списък с акции・Novocure Ltd

Novocure Ltd

Отворен

СекторЗдравеопазване

12.11 1.34

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.92

Максимум

12.2

Ключови измерители
By Trading Economics
Приходи	2.9M -37M
Продажби	8.4M 167M
EPS	-0.33
Марж на печалбата	-22.29
Служители	1,488
EBITDA	9.7M -26M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+137.66% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-256M 1.3B
Предишно отваряне	10.77
Предишно затваряне	12.11

Настроения в новините

By Acuity

100%

359 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

16.31 / 18.14 Подкрепа & съпротива

Novocure Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.11.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

BHP Abandons Bid for Anglo American Following New Talks

23.11.2025 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

23.11.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

23.11.2025 г., 19:00 ч. UTC

Печалби

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

23.11.2025 г., 00:50 ч. UTC

Печалби

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

22.11.2025 г., 10:30 ч. UTC

Печалби

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22.11.2025 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22.11.2025 г., 09:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 22:42 ч. UTC

Пазарно говорене

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 21:47 ч. UTC

Пазарно говорене

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21.11.2025 г., 21:43 ч. UTC

Пазарно говорене

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21.11.2025 г., 20:18 ч. UTC

Пазарно говорене

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21.11.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21.11.2025 г., 19:48 ч. UTC

Пазарно говорене

Precious Metals Fall for the Week -- Market Talk

21.11.2025 г., 19:44 ч. UTC

Печалби

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21.11.2025 г., 19:37 ч. UTC

Пазарно говорене

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21.11.2025 г., 19:20 ч. UTC

Пазарно говорене

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21.11.2025 г., 18:37 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21.11.2025 г., 18:34 ч. UTC

Пазарно говорене

Печалби

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21.11.2025 г., 18:28 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 18:03 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Intuit Seen on Path to Increase Growth -- Market Talk

21.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 17:05 ч. UTC

Пазарно говорене

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Novocure Ltd Прогноза

Ценова цел

By TipRanks

137.66% нагоре

12-месечна прогноза

Среден 28.4 USD 137.66%

Висок 42 USD

Нисък 18 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Novocure Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Novocure Ltd през последните 3 месеца.

Техническа оценка

By Trading Central

16.31 / 18.14Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.